» Articles » PMID: 11777970

Activated Human T Cells Accomplish MHC Class II Expression Through T Cell-specific Occupation of Class II Transactivator Promoter III

Overview
Journal J Immunol
Date 2002 Jan 5
PMID 11777970
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Activated human T cells express HLA-DR, HLA-DQ, and HLA-DP on their surface, but the regulation and functioning of MHC class II molecules in T lymphocytes are poorly understood. Because the MHC class II transactivator (CIITA) is essential for MHC class II expression, we have investigated transcriptional activation of CIITA in activated T cells. In this study, we show that in human activated CD4(+) T cells, CIITA promoter III (CIITA-PIII) drives the expression of CIITA. The in vivo genomic footprint analysis revealed activated T cell-specific occupation of CIITA-PIII. Subsequent EMSA analysis of several promoter regions showed differences in banding pattern among activated T cells, naive T cells, primary B cells, and Raji B cells. Activating response element (ARE)-1 is shown to interact with the acute myeloid leukemia 2 transcription factor in nuclear extracts derived from both T and B cells. Interestingly, the acute myeloid leukemia 3 transcription factor was bound in nuclear extracts of T cells only. The ARE-2 sequence is able to bind CREB/activating transcription factor family members in both T and B cells. In addition, a yet unidentified Ets family member was found to interact with site C in activated T cells, whereas in B cells site C was bound by PU.1 and Pip/IFN regulatory factor 4/IFN consensus sequence binding protein for activated T cells. In Jurkat T cells, both ARE-1 and ARE-2 are crucial for CIITA-PIII activity, similar to Raji B cells. The differential banding pattern in in vivo genomic footprinting and transcription factor binding at the ARE-1 and site C between T cells and B cells probably reflects differences in CIITA-PIII activation pathways employed by these cell types.

Citing Articles

High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells.

Fuchsl F, Untch J, Kavaka V, Zuleger G, Braun S, Schwanzer A Nat Commun. 2024; 15(1):10520.

PMID: 39627205 PMC: 11615276. DOI: 10.1038/s41467-024-53911-0.


Temporal Immune Profiling in the CSF and Blood of Patients with Aneurysmal Subarachnoid Hemorrhage.

Ujas T, Anderson K, Lutshumba J, Hart S, Turchan-Cholewo J, Hatton K medRxiv. 2024; .

PMID: 39228728 PMC: 11370545. DOI: 10.1101/2024.08.16.24312086.


Recent updates on allogeneic CAR-T cells in hematological malignancies.

Mansoori S, Noei A, Maali A, Seyed-Motahari S, Sharifzadeh Z Cancer Cell Int. 2024; 24(1):304.

PMID: 39227937 PMC: 11370086. DOI: 10.1186/s12935-024-03479-y.


A review of CD4 T cell differentiation and diversity in dogs.

Lang H, Osum K, Friedenberg S Vet Immunol Immunopathol. 2024; 275:110816.

PMID: 39173398 PMC: 11421293. DOI: 10.1016/j.vetimm.2024.110816.


Flow cytometric analysis of immune cell populations in the bronchial and mesenteric lymph nodes of the dromedary camel.

Hussen J, Althagafi H, Al-Sukruwah M, Falemban B, Abdul Manap A Front Vet Sci. 2024; 11:1365319.

PMID: 38746932 PMC: 11091912. DOI: 10.3389/fvets.2024.1365319.